Prostate cancer detection research and education

(a) Plan to develop and validate a test or tests for prostate cancer (1) In general The Secretary of Health and Human Services (referred to in this section as the Secretary), acting through the Director of the National Institutes of Health, shall establish an advisory council on prostate cancer (referred to in this section as the advisory council) to draft a plan for the development and validation of an accurate test or tests, such as biomarkers or imaging, to detect and diagnose prostate cancer. (2) Advisory council (A) Membership (i) Federal members The advisory council shall be composed of the following experts: (I) A designee of the Centers for Disease Control and Prevention. (II) A designee of the Centers for Medicare & Medicaid Services. (III) A designee of the Office of the Director of the National Cancer Institute. (IV) A designee of the Director of the Department of Defense Congressionally Directed Medical Research Programs. (V) A designee of the Director of the National Institute of Biomedical Imaging and Bioengineering. (VI) A designee of the Director of the National Institute of General Medical Sciences. (VII) A designee of the Director of the National Institute on Minority Health and Health Disparities. (VIII) A designee of the Director of the National Institutes of Health. (IX) A designee of the Commissioner of Food and Drugs. (X) A designee of the Director of the Agency for Healthcare Research and Quality. (XI) A designee of the Director of the Telemedicine and Advanced Technology Research Center of the Department of Defense. (ii) Non-federal members In addition to the members described in clause (i), the advisory council shall include 8 expert members from outside the Federal Government to be appointed by the Secretary, which shall include— (I) 2 prostate cancer patient advocates; (II) 2 health care providers with a range of expertise and experience in prostate cancer; and (III) 4 leading researchers with prostate cancer-related expertise in a range of clinical disciplines. (B) Meetings The advisory council shall meet quarterly and such meetings shall be open to the public. (C) Advice The advisory council shall advise the Secretary, or the Secretary’s designee. (D) Annual report Not later than 1 year after the date of enactment of this Act, the advisory council shall provide to the Secretary, or the Secretary’s designee, and Congress— (i) an initial evaluation of all federally funded efforts in prostate cancer research relating to the development and validation of an accurate test or tests to detect and diagnose prostate cancer; (ii) a plan for the development and validation of a reliable test or tests for the detection and accurate diagnosis of prostate cancer; and (iii) a set of standards for prostate cancer screening, developed in coordination with the United States Preventive Services Task Force, to ensure that any tools for screening, detection, and diagnosis developed in accordance with the plan under clause (ii) will meet the requirements of the Task Force for recommendation as a proven preventive or diagnostic service. (E) Termination The advisory council shall terminate on December 31, 2028. (3) Funding Notwithstanding any other provision of law, the Secretary may make available $1,000,000, from any unobligated amounts appropriated to the National Institutes of Health, for each of fiscal years 2027 through 2031 to carry out this subsection. (b) Coordination and intensification of prostate cancer research (1) In general The Director of the National Institutes of Health, in consultation with the Secretary of Defense, shall coordinate and intensify research in accordance with the plan provided under subsection (a)(2)(D)(ii), with particular attention provided to leveraging existing research to develop and validate a test or tests, such as biomarkers or imaging, to detect and accurately diagnose prostate cancer in order to improve quality of life for millions of individuals in the United States, and decrease health care system costs. (2) Funding Notwithstanding any other provision of law, the Secretary may make available $30,000,000, from any unobligated amounts appropriated to the National Institutes of Health, for each of fiscal years 2027 through 2031 to carry out this subsection.